Business Context and Reporting Period
This Form 8-K is a current report filed by Xenomics, Inc. (not Cardiff Oncology, Inc.) on April 16, 2009. The filing details a significant change in corporate governance and leadership structure following a shareholder consent delivered on the same date.
Key Financial Metrics
The filing text does not provide revenue, profit, cash flow, margin, debt, or liquidity figures. The report focuses exclusively on corporate governance changes and executive compensation arrangements.
Material Changes
- Removal of Director: Kira Sheinerman, Ph.D., was removed as a director and all authority to act on the Company's behalf was terminated.
- Appointment of New Chairman: Thomas H. Adams, Ph.D., was appointed to fill the vacancy and serve as Chairman of the Board.
- Executive Authority: Dr. Adams was granted authority to manage Company affairs, including evaluating business prospects, formulating strategy, relocating executive offices and research facilities to San Diego, and hiring executive officers pending the appointment of a full-time CEO.
- Board Control: The board authorized Dr. Adams to fill board vacancies exclusively from his nominees until April 30, 2010.
Guidance, Outlook, and Compensation
While no financial guidance is provided, the filing outlines a strategic shift toward relocating operations to San Diego and hiring new executive leadership. Dr. Adams was granted the following compensation:
- Stock Options: 4,800,000 ten-year options to purchase common stock at $0.50 per share, vesting in three equal annual installments.
- Consulting Stipend: A three-year term at an annual stipend of $100,000, payable monthly.
The filing notes that the Company is not registered under Section 12(g) of the Exchange Act, and the consent process was not subject to Section 14(a) or (c).
Investor Verification Checklist
- Verify the legal status of the shareholder consent and the removal of Dr. Sheinerman under Florida law.
- Confirm the timeline and progress of the planned relocation of executive offices and research facilities to San Diego.
- Monitor the search for and appointment of a full-time Chief Executive Officer.
- Review the impact of the 4.8 million option grant on existing shareholder dilution.
- Assess the strategic rationale for Dr. Adams' exclusive authority to nominate board members until April 2010.